City Therapeutics Announces Appointment of New CEO
City Therapeutics, Inc., a pioneering biopharmaceutical company in the field of RNA interference (RNAi)-based medicine, is excited to announce the recent appointment of Andrew “Andy” Orth as its new chief executive officer and director. With a remarkable career spanning over 25 years in biopharmaceutical research, development, and commercialization, Andy Orth brings an impressive track record. Most notably, he served as the chief commercial officer at Krystal Biotech and held key positions at Alnylam Pharmaceuticals, contributing significantly to the RNAi therapeutic landscape.
Welcome Statement from City Therapeutics Leadership
“We are thrilled to welcome Andy to City Therapeutics,” expressed John Maraganore, Ph.D., co-founder and executive chair of the company. “This is the right time to bring a CEO on board, as we rapidly advance our first RNAi-based program into clinical trials within the next few years.” He further emphasized his confidence in Andy’s diverse expertise in enhancing the company’s capabilities, marking a new era for City Therapeutics.
Andy Orth's Vision for City Therapeutics
In his role as CEO, Andy Orth will spearhead cross-functional business strategies to drive operational efficiency and sustainable growth. His leadership will be crucial as the company progresses into clinical and commercial development stages, focusing on innovations in RNAi trigger molecules that pave the way for improved therapeutic outcomes across various diseases.
Andy Orth's Previous Achievements
Prior to his role at City Therapeutics, Mr. Orth excelled as chief commercial officer at Krystal Biotech, where he was integral to the global commercialization of groundbreaking therapies, including the pioneering topical gene therapy, VYJUVEK®. His prior experience at Alnylam Pharmaceuticals involved significant responsibilities, such as leading the launch of the first-ever RNAi therapeutic, ONPATTRO®, and subsequent products GIVLAARI® and OXLUMO®. His background also includes several pivotal roles at Biogen, focusing on global commercial strategy.
Educational Background and Early Career
Orth's foundational career included roles at Genzyme and Amgen, where he developed a strong reputation. His academic credentials, including an MBA from the Johnson Graduate School of Management at Cornell University, and his undergraduate studies at the University of Wisconsin, showcase his commitment to excellence in his field.
About City Therapeutics
City Therapeutics stands at the forefront of RNAi therapeutics, dedicated to enhancing the engineering of RNAi trigger molecules. The company is committed to developing a robust pipeline of innovative solutions aimed at addressing disparate therapeutic needs across patient demographics. Co-founded by industry visionaries, City Therapeutics has an impressive backing of $135 million from leading investors in life sciences, positioning it for impactful advancements in medication.
Frequently Asked Questions
What is the main focus of City Therapeutics?
City Therapeutics specializes in RNA interference (RNAi)-based medicines, developing innovative solutions for various diseases.
Who is the new CEO of City Therapeutics?
The new CEO is Andrew “Andy” Orth, who has extensive experience in the biopharmaceutical industry.
What previous roles did Andy Orth hold before becoming CEO?
Before joining City Therapeutics, he was the chief commercial officer at Krystal Biotech and had significant roles at Alnylam Pharmaceuticals and Biogen.
What does the leadership hope to achieve with Andy Orth?
They aim to advance their RNAi program into clinical trials and strengthen the company’s operational excellence and growth.
What is the significance of RNAi therapeutics?
RNAi therapeutics hold potential to revolutionize treatment approaches for a variety of genetic and chronic diseases, offering targeted therapies that can transform patient outcomes.
